Los Angeles Capital Management LLC Invests $1.10 Million in NeoGenomics, Inc. (NASDAQ:NEO)

Los Angeles Capital Management LLC acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 74,633 shares of the medical research company's stock, valued at approximately $1,101,000. Los Angeles Capital Management LLC owned about 0.06% of NeoGenomics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Blue Trust Inc. grew its holdings in NeoGenomics by 107.2% during the 2nd quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company's stock valued at $32,000 after purchasing an additional 1,206 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of NeoGenomics during the second quarter valued at approximately $57,000. Banque Cantonale Vaudoise raised its holdings in shares of NeoGenomics by 10.2% in the second quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company's stock worth $244,000 after buying an additional 1,633 shares during the period. Gabelli Funds LLC bought a new stake in shares of NeoGenomics during the 1st quarter worth approximately $283,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of NeoGenomics during the first quarter valued at $314,000. Hedge funds and other institutional investors own 98.50% of the company's stock.

NeoGenomics Stock Performance

Shares of NEO traded down $0.74 during trading hours on Friday, hitting $15.05. The stock had a trading volume of 352,841 shares, compared to its average volume of 818,560. The firm has a 50-day moving average price of $14.69 and a 200 day moving average price of $14.81. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. NeoGenomics, Inc. has a fifty-two week low of $12.77 and a fifty-two week high of $21.22. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -25.56 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.04. The firm had revenue of $167.80 million for the quarter, compared to analysts' expectations of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The firm's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.06) EPS. As a group, research analysts anticipate that NeoGenomics, Inc. will post -0.17 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Needham & Company LLC reissued a "buy" rating and set a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, November 6th. Stephens restated an "overweight" rating and issued a $19.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. Finally, Benchmark reiterated a "buy" rating and set a $18.00 price objective on shares of NeoGenomics in a report on Tuesday, September 24th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, NeoGenomics currently has a consensus rating of "Buy" and a consensus target price of $20.25.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.